Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2014-12-04

FDA Approved: LASTACAFT — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

FDA approves Allergan's supplemental application for LASTACAFT (alcaftadine), leading to changes in the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lastacaft (Alcaftadine)

Snippet

SUPPL AP for LASTACAFT (ALCAFTADINE)